New Pharmacologic Therapies in Gastrointestinal Disease

Gastroenterology Clinics of North America

Volumn 39, Issue 3, 2010, Pages 709-720

  Wallace, John L ^a   Ferraz, Jose G P ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acid; Inflammation; Irritable bowel; Nonsteroidal anti inflammatory drug; Ulcer

Indexed keywords

17 METHYLNALTREXONE BROMIDE; ACETYLSALICYLIC ACID; AGN 201904 Z; ALVIMOPAN; AXANUM; BENATOPRAZOLE; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; DM 3458; FAMOTIDINE; GASTROINTESTINAL AGENT; GUANYLATE CYCLASE INHIBITOR; ILAPRAZOLE; LINACLOTIDE; LUBIPROSTONE; OMEPRAZOLE; OPIATE; PENNSAID; PLACEBO; PN 100; PN 200; POTASSIUM COMPETITIVE ACID BLOCKER; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; ROFECOXIB; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECAM; VIMOVO;

ACID SECRETION; ANTINOCICEPTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY DISORDER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INTESTINE PSEUDOOBSTRUCTION; LOW DRUG DOSE; PEPTIC ULCER; REVIEW; SHORT BOWEL SYNDROME; SINGLE DRUG DOSE; STOMACH PARESIS; STOMACH PARIETAL CELL; STOMACH PROTECTION; STRESS ULCER; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONSTIPATION; ENZYME INHIBITORS; GASTRIC ACID; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE H2 ANTAGONISTS; HUMANS; POTASSIUM; PROTON PUMP INHIBITORS; SEROTONIN RECEPTOR AGONISTS; SHORT BOWEL SYNDROME;

EID: 77957927410     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.08.020     Document Type: Review

References (40)

1. Scarpignato C., Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning. Curr Opin Pharmacol 2008, 8:677-684.
2. Chey W.D., Mody R., Kothari S., et al. Are proton pump inhibitors (PPIs) sufficient in controlling symptoms of gastro-esophageal reflux disease (GERD)? a community-based US survey study. Gastroenterology 2008, 124(Suppl 1):A325.
3. Tutuian R., Katz P.O., Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004, 16:441-443.
4. +-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol 2007, 73:198-205.
5. Simon W.A., Hermann M., Klein T., et al. Soprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007, 321:866-874.
6. Rackoff A., Agrawal A., Hila A., et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005, 18:370-373.
7. Fandriks L., Lonroth H., Pettersen A., et al. Can famotidine and omeprazole be combined on a once-daily basis?. Scand J Gastroenterol 2007, 42:689-694.
8. Gershon M.D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
9. Bouras E.P., Camilleri M., Burton D.D., et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999, 44:682-686.
10. Gale J.D. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Adv Ther 2009, 26:519-530.
11. Tack J., Van Outryve M., Beyens G., et al. Prucalopride (resolor(R)) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009, 58:357-365.
12. + channel and the common T897 polymorph. Eur J Pharmacol 2007, 554:98-105.
13. Carter N.J., Scott L.J. Lubiprostone. In constipation-predominant irritable bowel syndrome. Drugs 2009, 69:1229-1237.
14. Lembo A.J., Kurtz C.B., MacDougall J.E., et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010, 138:886-895.
15. Kraft M., MacLaren R., Du W., et al. Alvimopan (Entereg) for the management of postoperative ileus in patients undergoing bowel resection. Pharmacol Ther 2010, 35:44-49.
16. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009, 155:11-17.
17. Wallace J.L. Selective COX-2 inhibitors: is the water becoming muddy?. Trends Pharmacol Sci 1999, 20:4-6.
18. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol Rev 2008, 88:1547-1565.
19. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002, 123:1598-1606.
20. Fiorucci S., Santucci L., Wallace J.L., et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A 2003, 100:10937-10941.
21. Lanas A., Baron J.A., Sandler R.S., et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007, 132:490-497.
22. Laine L., Maller E.S., Yu C., et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004, 127:395-402.
23. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
24. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 12(369):1621-1626.
25. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435-1439.
26. Moen M.D. Topical diclofenac solution. Drugs 2009, 69:2621-2632.
27. Lichtenberger L.M., Barron M., Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009, 45:877-890.
28. Lanza F.L., Marathi U.K., Anand B.S., et al. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008, 28:431-442.
29. Wallace J.L. The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994, 72:1493-1498.
30. Wallace J.L., Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003, 17:11-20.
31. Wallace J.L., Viappiani S., Bolla M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 2009, 30:112-117.
32. Karlsson J., Pivodic A., Aguirre D., et al. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009, 36:1290-1297.
33. White W.B., Schnitzer T.J., Fleming R., et al. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009, 109:840-845.
34. Fiorucci S., Distrutti E., Cirino G., et al. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006, 131:259-271.
35. Wallace J.L., Dicay M., McKnight W., et al. Hydrogen sulfide enhances ulcer healing in rats. FASEB J 2007, 21:4070-4076.
36. Wallace J.L., Caliendo G., Santagada V., et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132:1261-1271.
37. Wallace J.L. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 2007, 28:501-505.
38. Wallace J.L., Caliendo G., Santagada V., et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010, 159:1236-1246.
39. Drucker D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005, 1:22-31.
40. Jeppesen P.B., Sanguinetti E.L., Buchman A., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005, 54:1224-1231.